Accès ouvert déclaré2022preprint

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir

Brian Epling, Joseph M. Rocco, Kristin L. Boswell, Elizabeth Laidlaw, Frances Galindo, Anela Kellogg, Sanchita Das, Allison Roder, Elodie Ghedin, Allie Kreitman, Robin Dewar, Sophie Kelly, Heather Kalish, Tauseef Ur Rehman, Jeroen Highbarger, Adam Rupert, Gregory Kocher, Michael R. Holbrook, Andrea Lisco, Maura Manion, Richard A. Koup, Irini Sereti

11Citations signalées
7Institutions associées
1Pays d’affiliation

Résumé fourni par la source

Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.

Institutions

National Institutes of HealthNational Institute of Allergy and Infectious DiseasesLeidos (United States)Frederick National Laboratory for Cancer ResearchLeidos Biomedical Research Inc. (United States)National Institutes of Health Clinical CenterNational Institute of Biomedical Imaging and Bioengineering

Sujets associés

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies
Lire en accès ouvert Voir la notice officielleDOI

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.